Literature DB >> 28805789

Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome.

L Kumar1, R Gogi1, A K Patel1, A Mookerjee1, R K Sahoo1, P S Malik1, A Sharma1, S Thulkar2, R Kumar3, A Biswas4, O D Sharma5, R Gupta5.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28805789     DOI： 10.1038/bmt.2017.165

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.

Authors:  Mathew Weinstock; Yosra Aljawai; Elizabeth A Morgan; Jacob Laubach; Muriel Gannon; Aldo M Roccaro; Cindy Varga; Constantine S Mitsiades; Claudia Paba-Prada; Robert Schlossman; Nikhil Munshi; Kenneth C Anderson; Paul P Richardson; Edie Weller; Irene M Ghobrial
Journal:  Br J Haematol       Date:  2015-04-01       Impact factor: 6.998

2.  Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.

Authors:  Shuhui Deng; Yan Xu; Gang An; Weiwei Sui; Dehui Zou; Yaozhong Zhao; Junyuan Qi; Fei Li; Mu Hao; Lugui Qiu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-01-03

3.  The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.

Authors:  Ho-Jin Shin; Kihyun Kim; Je-Jung Lee; Moo-Kon Song; Eun Yup Lee; Sang Hyuk Park; Sun-Hee Kim; Mi-Ae Jang; Seok Jin Kim; Joo Seop Chung
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-12

4.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Authors:  Joaquin Martinez-Lopez; Joan Blade; María-Victoria Mateos; Carlos Grande; Adrián Alegre; José García-Laraña; Anna Sureda; Javier de la Rubia; Eulogio Conde; Rafael Martinez; Felipe de Arriba; Maria C Viguria; Joan Besalduch; Rafael Cabrera; José D Gonzalez-San Miguel; José Luis Guzman-Zamudio; Maria Carmen Gomez del Castillo; José Maria Moraleda; Juan C García-Ruiz; Jesús San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

5.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Authors:  Saad Z Usmani; Christoph Heuck; Alan Mitchell; Jackie Szymonifka; Bijay Nair; Antje Hoering; Yazan Alsayed; Sarah Waheed; Sajjad Haider; Alejandro Restrepo; Frits Van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 6.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.

Authors:  Joan Bladé; Carlos Fernández de Larrea; Laura Rosiñol; María Teresa Cibeira; Raquel Jiménez; Ray Powles
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

7.  Autologous stem cell transplantation for multiple myeloma: Long-term results.

Authors:  Lalit Kumar; Rakesh Reddy Boya; Rohit Pai; P Harish; Anjali Mookerjee; B Sainath; Mukesh Bhimrao Patekar; Ranjit Kumar Sahoo; Prabhat Singh Malik; O D Sharma; Ritu Gupta
Journal:  Natl Med J India       Date:  2016 Jul-Aug       Impact factor: 0.537

8.  Extramedullary multiple myeloma escapes the effect of thalidomide.

Authors:  Laura Rosiñol; Ma Teresa Cibeira; Joan Bladé; Jordi Esteve; Marta Aymerich; María Rozman; Marta Segarra; Maria C Cid; Xavier Filella; Emili Montserrat
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

9.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

10.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Authors:  Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Dolores Hernández; Javier López-Jiménez; Javier de la Rubia; Miquel Granell; Joan Besalduch; Luis Palomera; Yolanda González; María Asunción Etxebeste; Joaquín Díaz-Mediavilla; Miguel T Hernández; Felipe de Arriba; Norma C Gutiérrez; María Luisa Martín-Ramos; María Teresa Cibeira; María Victoria Mateos; Joaquín Martínez; Adrián Alegre; Juan José Lahuerta; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113
View more
  7 in total

Review 1.  Advances in the treatment of extramedullary disease in multiple myeloma.

Authors:  Yating Li; Zhengxu Sun; Xiaoyan Qu
Journal:  Transl Oncol       Date:  2022-06-06       Impact factor: 4.803

Review 2.  High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.

Authors:  Antonio Giovanni Solimando; Matteo Claudio Da Vià; Sebastiano Cicco; Patrizia Leone; Giuseppe Di Lernia; Donato Giannico; Vanessa Desantis; Maria Antonia Frassanito; Arcangelo Morizio; Julia Delgado Tascon; Assunta Melaccio; Ilaria Saltarella; Giuseppe Ranieri; Roberto Ria; Leo Rasche; K Martin Kortüm; Andreas Beilhack; Vito Racanelli; Angelo Vacca; Hermann Einsele
Journal:  J Clin Med       Date:  2019-07-09       Impact factor: 4.241

3.  A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Authors:  Meral Beksac; Guldane Cengiz Seval; Nicholas Kanellias; Daniel Coriu; Laura Rosiñol; Gulsum Ozet; Vesselina Goranova-Marinova; Ali Unal; Jelena Bila; Hayri Ozsan; Arben Ivanaj; Lejla Ibricevic Balić; Efstathios Kastritis; Joan Bladé; Meletios Athanasios Dimopoulos
Journal:  Haematologica       Date:  2019-07-05       Impact factor: 9.941

Review 4.  Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance.

Authors:  Vincenzo Sammartano; Alfonso Cerase; Valentina Venanzi; Maria Antonietta Mazzei; Beatrice Esposito Vangone; Francesco Gentili; Ivano Chiarotti; Monica Bocchia; Alessandro Gozzetti
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

5.  Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.

Authors:  Ying Wang; Aijun Liu; Tingting Xu; Jiahui Yin; Wenming Chen
Journal:  Clin Med Insights Oncol       Date:  2022-07-18

Review 6.  Extramedullary disease in multiple myeloma.

Authors:  Radhika Bansal; Sagar Rakshit; Shaji Kumar
Journal:  Blood Cancer J       Date:  2021-09-29       Impact factor: 11.037

7.  Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.

Authors:  Wei Li; Meijing Liu; Ting Yuan; Lixiang Yan; Rui Cui; Qi Deng
Journal:  Hematol Oncol       Date:  2022-01-10       Impact factor: 4.850
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.